A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma (Q36381565)

13 August 2017

1 reference

title

A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma (English)

1 reference

13 August 2017

phase II clinical trial

0 references

0 references

1 reference

5

Hartmut Goldschmidt

1 reference

13 August 2017

Axel Glasmacher

1

1 reference

13 August 2017

Corinna Hahn

2

1 reference

13 August 2017

Florian Hoffmann

3

1 reference

13 August 2017

Ralph Naumann

4

1 reference

13 August 2017

Marie von Lilienfeld-Toal

6

1 reference

13 August 2017

Katjana Orlopp

7

1 reference

13 August 2017

Ingo Schmidt-Wolf

8

1 reference

13 August 2017

Marcus Gorschlüter

9

1 reference

13 August 2017

language of work or name

English

0 references

publication date

1 March 2006

1 reference

British Journal of Haematology

13 August 2017

1 reference

13 August 2017

132

1 reference

13 August 2017

584-593

1 reference

13 August 2017

5

1 reference

Thalidomide with or without dexamethasone for refractory or relapsing multiple myeloma

13 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05914.X

Thalidomide and dexamethasone for resistant multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05914.X

Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05914.X

Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05914.X

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05914.X

Thalidomide in multiple myeloma: current status and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05914.X

Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05914.X

Thalidomide and dexamethasone combination for refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05914.X

Treatment of plasma cell dyscrasias with thalidomide and its derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05914.X

Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05914.X

The current status of thalidomide in the management of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05914.X

Australia approves thalidomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05914.X

Reduction of leukocyte count is associated with thalidomide response in treatment of multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05914.X

Thalidomide in low doses is effective for the treatment of resistant or relapsed multiple myeloma and for plasma cell leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05914.X

Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05914.X

Thalidomide for the treatment of refractory multiple myeloma: association of plasma concentrations of thalidomide and angiogenic growth factors with clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05914.X

Low dose thalidomide in patients with relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05914.X

Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05914.X

Efficacy of a low dose of thalidomide in advanced multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05914.X

Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05914.X

Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05914.X

Analysis of durability of response to thalidomide treatment for relapsed myeloma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05914.X

Deep venous thrombosis and thalidomide therapy for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05914.X

Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05914.X

An UK myeloma forum phase II study of thalidomide; long term follow-up and recommendations for treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05914.X

Antitumor activity of thalidomide in refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05914.X

Early response predicts thalidomide efficiency in patients with advanced multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05914.X

Thalidomide alone or with dexamethasone for previously untreated multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05914.X

Intermediate dose thalidomide (200 mg daily) has comparable efficacy and less toxicity than higher doses in relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05914.X

Thalidomide in patients with advanced multiple myeloma: a study of 83 patients--report of the Intergroupe Francophone du Myélome (IFM).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05914.X

Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05914.X

Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05914.X

The blood coagulation mechanism in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05914.X

Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05914.X

Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05914.X

10.1111/J.1365-2141.2005.05914.X

21 January 2018

Identifiers

DOI

1 reference

13 August 2017

1 reference